Anavex Life Sciences (AVXL) Scheduled to Post Quarterly Earnings on Monday

Anavex Life Sciences (NASDAQ:AVXL) will issue its quarterly earnings data on Monday, December 11th. Analysts expect the company to announce earnings of ($0.10) per share for the quarter.

Anavex Life Sciences (NASDAQ AVXL) opened at $3.74 on Monday. Anavex Life Sciences has a 12 month low of $3.33 and a 12 month high of $6.64.

AVXL has been the topic of a number of research reports. Zacks Investment Research raised shares of Anavex Life Sciences from a “hold” rating to a “buy” rating and set a $5.00 target price on the stock in a research note on Monday, September 18th. Maxim Group set a $15.00 target price on shares of Anavex Life Sciences and gave the stock a “buy” rating in a research note on Monday, October 30th. ValuEngine lowered shares of Anavex Life Sciences from a “hold” rating to a “sell” rating in a research note on Tuesday, November 21st. Finally, Noble Financial reissued a “buy” rating on shares of Anavex Life Sciences in a research note on Wednesday, August 9th.

A hedge fund recently raised its stake in Anavex Life Sciences stock. The Manufacturers Life Insurance Company grew its holdings in Anavex Life Sciences Corp. (NASDAQ:AVXL) by 37.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,876 shares of the biotechnology company’s stock after purchasing an additional 8,728 shares during the quarter. The Manufacturers Life Insurance Company owned about 0.08% of Anavex Life Sciences worth $169,000 as of its most recent SEC filing. 23.32% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at

About Anavex Life Sciences

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

Earnings History for Anavex Life Sciences (NASDAQ:AVXL)

What are top analysts saying about Anavex Life Sciences Corp.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Anavex Life Sciences Corp. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit